| Citation: |
GE Zheng-dan, ZHOU Nian-wei, TIAN Fang-yan, et al. Analysis of features of three-dimensional echocardiography in patients with Fabry disease induced by GLA mutation[J]. Chin J Clin Med, 2023, 30(4): 636-640. DOI: 10.12025/j.issn.1008-6358.2023.20230510
|
To evaluate the changes of endocardial echo and left ventricular global longitudinal systolic function in a Fabry disease (FD) family with GLA gene mutation by three-dimensional echocardiography (3DE).
A FD family included 8 members diagnosed in Zhongshan Hospital, Fudan University in October 2022 were enrolled. 2DE and 3DE images were performed in all participants. The myocardial deformation values of left ventricle were measured by TomTec Imaging Systems.
Of 8 FD patients, 7 carried the GLA gene mutation (NM_000169.2: c.902G > A, p.Arg301Gln). Endocardial echoes were enhanced in all patients, and "binary sign" occurred in the first certifier and his first-degree relatives (n＝5). And global longitudinal systolic function of the left ventricle in all patients was decreased, which was manifested as the global longitudinal strain (GLS).
The longitudinal systolic function of left ventricle decreased combined with endocardial echo enhancement in 3DE could indicate FD early.
| [1] |
中国法布雷病专家协作组. 中国法布雷病诊疗专家共识(2021年版)[J]. 中华内科杂志, 2021, 60(4): 321-330.
Chinese Fabry Disease Expert Panel. Expert consensus for diagnosis and treatment of Fabry disease in China (2021)[J]. Chin J Intern Med, 2021, 60(4): 321-330.
|
| [2] |
LANG R M, BADANO L P, MOR-AVI V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(3): 233-270. DOI: 10.1093/ehjci/jev014
|
| [3] |
LU D Y, HUANG W M, WANG W T, et al. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy[J]. Eur Heart J Cardiovasc Imaging, 2022, 23(4): 487-495. DOI: 10.1093/ehjci/jeab214
|
| [4] |
ESPOSITO R, SANTORO C, SORRENTINO R, et al. Layer-specific longitudinal strain in Anderson-Fabry disease at diagnosis: a speckle tracking echocardiography analysis[J]. Echocardiography, 2019, 36(7): 1273-1281. DOI: 10.1111/echo.14399
|
| [5] |
RAVAROTTO V, SIMIONI F, CARRARO G, et al. Oxidative stress and cardiovascular-renal damage in fabry disease: is there room for a pathophysiological involvement?[J]. J Clin Med, 2018, 7(11): 409. DOI: 10.3390/jcm7110409
|
| [6] |
ROZENFELD P, FERIOZZI S. Contribution of inflammatory pathways to Fabry disease pathogenesis[J]. Mol Genet Metab, 2017, 122(3): 19-27. DOI: 10.1016/j.ymgme.2017.09.004
|
| [7] |
WEIDEMANN F, SANCHEZ-NIÑO M D, POLITEI J, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications[J]. Orphanet J Rare Dis, 2013, 8: 116. DOI: 10.1186/1750-1172-8-116
|
| [8] |
AERTS J M, GROENER J E, KUIPER S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease[J]. Proc Natl Acad Sci U S A, 2008, 105(8): 2812-2817. DOI: 10.1073/pnas.0712309105
|
| [9] |
BRAKCH N, DORMOND O, BEKRI S, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease[J]. Eur Heart J, 2010, 31(1): 67-76. DOI: 10.1093/eurheartj/ehp387
|
| [10] |
MIRZAIAN M, WISSE P, FERRAZ M J, et al. Accurate quantification of sphingosine-1-phosphate in normal and Fabry disease plasma, cells and tissues by LC-MS/MS with (13)C-encoded natural S1P as internal standard[J]. Clin Chim Acta, 2016, 459: 36-44. DOI: 10.1016/j.cca.2016.05.017
|
| [11] |
PIERONI M, CHIMENTI C, COBELLI F D, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization[J]. J Am Coll Cardiol, 2006, 47(8): 1663-1671. DOI: 10.1016/j.jacc.2005.11.070
|
| [12] |
KOSKENVUO J W, ENGBLOM E, KANTOLA I M, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance[J]. Clin Physiol Funct Imaging, 2009, 29(3): 177-180. DOI: 10.1111/j.1475-097X.2008.00851.x
|
| [13] |
KOUNAS S, DEMETRESCU C, PANTAZIS A A, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2008, 51(21): 2058-2061. DOI: 10.1016/j.jacc.2008.02.046
|
| [14] |
PEDRIZZETTI G, CLAUS P, KILNER P J, et al. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use[J]. J Cardiovasc Magn Reson, 2016, 18(1): 51. DOI: 10.1186/s12968-016-0269-7
|
| [15] |
NABESHIMA Y, SEO Y, TAKEUCHI M. A review of current trends in three-dimensional analysis of left ventricular myocardial strain[J]. Cardiovasc Ultrasound, 2020, 18(1): 23. DOI: 10.1186/s12947-020-00204-3
|
| [16] |
AVEGLIANO G P, COSTABEL J P, ASCH F M, et al. Utility of real time 3D echocardiography for the assessment of left ventricular mass in patients with hypertrophic cardiomyopathy: comparison with cardiac magnetic resonance[J]. Echocardiography, 2016, 33(3): 431-436. DOI: 10.1111/echo.13096
|
| [17] |
KRÄMER J, NIEMANN M, LIU D, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease[J]. Eur Heart J, 2013, 34(21): 1587-1596. DOI: 10.1093/eurheartj/eht098
|
DownLoad: